Polaryx Therapeutics, Inc. Common Stock
PLYX
Get informed when a big investor buys or sells
+ FollowMarket Cap$113.65M
Close$
$0.11
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $113.65 Million |
|---|---|
| Enterprise Value | $110.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | -9.92 |
| Outstanding Shares | 47,219,329 |
Return
| Return on Equity | -260.33% |
|---|---|
| Return on Assets | -184.95% |
| Return on Invested Capital | -189.99% |
Valuation & Multiples
| P/E Ratio | -23.17 |
|---|---|
| PEG | 46.67 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -23.39 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.80%▲ 4.80% |
|---|---|
| Total Invested | $17.14M |
| Investors Holding | 14▲ 14.00% |
ESG Score
No data
About Polaryx Therapeutics, Inc. Common Stock
11 employees
CEO: Alex Yang Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement...